Immunic (IMUX) vs Rani Therapeutics (RANI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Rani Therapeutics (RANI) has outperformed Immunic (IMUX) over the past year, gaining 61.6% versus a loss of 15.8%. Over five years, IMUX leads with a -91.3% price change compared with -96.0% for RANI. Rani Therapeutics is the larger company by market cap ($112.4 million vs $111.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMUX | RANI |
|---|---|---|
| Share price | $8.15 | $0.80 |
| Market cap | $111.20M | $112.42M |
| 1-day change | +7.80% | +1.01% |
| YTD return | +41.57% | -41.33% |
| 1-year return | -15.81% | +61.63% |
| 5-year return | -91.28% | -95.98% |
| EPS (TTM) | $-3.83 | $-0.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.43 | $3.87 |
| 52-week low | $5.06 | $0.445 |
| Distance from 52-week high | -53.24% | -79.33% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +428.71% | +800.00% |
| Average volume | 284.68K | 743.68K |
| Shares outstanding | 13.64M | 115.42M |
| Employees | 100 | 69 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RANI has outperformed IMUX by 77.4 percentage points over the past year.
About Immunic
IMUX stock →Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
About Rani Therapeutics
RANI stock →Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
IMUX vs RANI FAQ
Which is bigger, Immunic or Rani Therapeutics?
Rani Therapeutics (RANI) is larger, with a market capitalization of $112.42M compared with $111.20M for Immunic (IMUX).
Which stock has performed better over the past year, IMUX or RANI?
RANI returned +61.63% over the past 12 months, compared with -15.81% for IMUX (price return, excluding dividends). Past performance does not predict future results.
Are Immunic and Rani Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.